ST凯利拟将对动之医学持股比例提高至50.9014% 其主营再生诱导系列产品

Core Viewpoint - The company plans to invest in Dongzhi Medical Technology (Shanghai) Co., Ltd. by acquiring equity and subscribing to new registered capital, increasing its ownership stake to 50.9014% from 37.9528% [1] Investment Details - The investment involves acquiring shares from existing shareholders Shanghai Lisei Management Consulting Partnership (Limited Partnership) and Yuan Zheng, who will exit Dongzhi Medical [1] - The company will also inject an additional capital of 20 million yuan into Dongzhi Medical [1] Company Profile - Dongzhi Medical specializes in the research, production, and sales of regenerative induction series products, including regenerative induction biological patches, active cell patches, umbilical cord stem cell preparations, and amniotic membrane gel dressings [1] - The registered capital of Dongzhi Medical is 1.783679 million yuan [1] Competitive Advantage - The biological patch products of Dongzhi Medical enhance the company's competitiveness in the field of research and production of regenerative induction series products [1] - The products have completed pre-market clinical trials [1]